Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin

References

• Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Women’s Health. 2019;11:287–299. doi:10.2147/IJWH.S19760431118829
   PubMed Web of Science ®Google Scholar
• Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451–2460. doi:10.1002/ijc.v140.1128257597
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer. 2003;13(Suppl 2):144–148.14656271
   PubMedGoogle Scholar
• Bergamini A, Bocciolone L, Fodor A, Candiani M, Mangili G. Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option. Int J Gynecologic Cancer. 2019;ijgc-2019-000624.
   PubMedGoogle Scholar
• Khalifa AM, Elsheikh MA, Khalifa AM, Elnaggar YSR. Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: a review article. J Controlled Release. 2019;311–312:125–137. doi:10.1016/j.jconrel.2019.08.034
   PubMed Web of Science ®Google Scholar
• Parmar MKLJ, Colombo N, Du Bois A, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099–2106.12826431
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–4707. doi:10.1200/JCO.2006.06.091316966687
   PubMed Web of Science ®Google Scholar
• Sehouli J, Chekerov R, Reinthaller A, et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-study group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann Oncol. 2016;27(12):2236–2241. doi:10.1093/annonc/mdw41827789470
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323–3329. doi:10.1200/JCO.2009.25.751920498395
   PubMed Web of Science ®Google Scholar
• Brundage M, Gropp M, Mefti F, et al. Health-related quality of life in recurrent platinum-sensitive ovarian cancer – results from the CALYPSO trial. Ann Oncol. 2012;23(8):2020–2027. doi:10.1093/annonc/mdr58322291207
   PubMed Web of Science ®Google Scholar
• Shanmuganathan R, Edison TNJI, LewisOscar F, Kumar P, Shanmugam S, Pugazhendhi A. Chitosan nanopolymers: an overview of drug delivery against cancer. Int J Biol Macromol. 2019;130:727–736. doi:10.1016/j.ijbiomac.2019.02.06030771392
   PubMed Web of Science ®Google Scholar
• Pugazhendhi A, Edison TNJI, Velmurugan BK, Jacob JA, Karuppusamy I. Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci. 2018;200:26–30. doi:10.1016/j.lfs.2018.03.02329534993
   PubMed Web of Science ®Google Scholar
• Yamada Y, Kawaguchi R, Ito F, et al. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer. J Obstet Gynaecol Res. 2017;43(7):1194–1199. doi:10.1111/jog.2017.43.issue-728544386
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, et al. Barenholz Y: prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4):987.8313389
   PubMed Web of Science ®Google Scholar
• Lorusso D, Sabatucci I, Maltese G, et al. Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis. Tumori J. 2019;105(4):282–287. doi:10.1177/0300891619839308
   PubMed Web of Science ®Google Scholar
• Hong R-L, Tseng Y-L. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors. Cancer. 2001;91(9):1826–1833. doi:10.1002/(ISSN)1097-014211335910
   PubMed Web of Science ®Google Scholar
• Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107(4):588–591. doi:10.1038/bjc.2012.30722836511
   PubMed Web of Science ®Google Scholar
• Ferrero JM, Weber B, Geay JF, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol. 2007;18(2):263–268. doi:10.1093/annonc/mdl37617108151
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Wilczynski SP, et al., Southwest Oncology G. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol. 2008;108(1):90–94. doi:10.1016/j.ygyno.2007.08.07517949799
   PubMed Web of Science ®Google Scholar
• Power P, Stuart G, Oza A, et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol. 2009;114(3):410–414. doi:10.1016/j.ygyno.2009.04.03719520420
   PubMed Web of Science ®Google Scholar
• Bafaloukos D, Linardou H, Aravantinos G, et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Med. 2010;8:3. doi:10.1186/1741-7015-8-320055981
   PubMed Web of Science ®Google Scholar
• Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–2612. doi:10.1093/annonc/mds20322910840
   PubMed Web of Science ®Google Scholar
• Jiménez-Sánchez A, Memon D, Pourpe S, et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell. 2017;170(5):927–938.e920. doi:10.1016/j.cell.2017.07.02528841418
   PubMed Web of Science ®Google Scholar
• Roberts CM, Cardenas C, Tedja R. The role of intra-tumoral heterogeneity and its clinical relevance in epithelial ovarian cancer recurrence and metastasis. Cancers. 2019;11(8):1083. doi:10.3390/cancers11081083
   PubMed Web of Science ®Google Scholar
• Hollis RL, Gourley C, L Hollis R. Genetic and molecular changes in ovarian cancer. Cancer Biol Med. 2016;13(2):236–247. doi:10.20892/j.issn.2095-3941.2016.002427458531
   PubMed Web of Science ®Google Scholar
• Safra T, Borgato L, Nicoletto MO, et al. Grenader TJMct: BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther. 2011;10(10):2000–2007. doi:10.1158/1535-7163.MCT-11-027221835933
   PubMed Web of Science ®Google Scholar
• Tan DS, Rothermundt C, Thomas K, et al. Gore MEJJoCO: “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26(34):5530–5536. doi:10.1200/JCO.2008.16.170318955455
   PubMed Web of Science ®Google Scholar
• Hollis RL, Churchman M, Gourley CJO. Therapy: distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. OncoTargets Ther. 2017;10:2539.
   PubMed Web of Science ®Google Scholar
• Hollis RL, Meynert AM, Churchman M, et al. Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.  BMC Cancer. 2018 Jan 3;18(1):16.  doi:10.1186/s12885-017-3981
   Google Scholar
• Gourley C, Michie CO, Roxburgh P, et al. Reed NJJoCO: increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol. 2010;28(15):2505–2511. doi:10.1200/JCO.2009.25.108220406939
   PubMed Web of Science ®Google Scholar
• Adams SF, Marsh EB, Elmasri W, et al. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;123(3):486–491. doi:10.1016/j.ygyno.2011.08.03221945552
   PubMed Web of Science ®Google Scholar
• Safra T, Borgato L, Nicoletto MO, et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther. 2011;10(10):2000–2007. doi:10.1158/1535-7163.MCT-11-027221835933
   PubMed Web of Science ®Google Scholar
• Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 2007;13(24):7413–7420. doi:10.1158/1078-0432.CCR-07-108318094425
   PubMed Web of Science ®Google Scholar
• Tan DSP, Yap TA, Hutka M, et al. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer. 2013;49(6):1246–1253. doi:10.1016/j.ejca.2012.11.01623265709
   PubMed Web of Science ®Google Scholar
• Mayor P, Gay LM, Lele S, Elvin JA. BRCA1 reversion mutation acquired after treatment identified by liquid biopsy. Gynecologic Oncol Rep. 2017;21:57–60. doi:10.1016/j.gore.2017.06.010
   PubMed Web of Science ®Google Scholar
• Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs. 2019;79(11):1231–1239. doi:10.1007/s40265-019-01158-131267481
   PubMed Web of Science ®Google Scholar
• Shoji T, Eto H, Sato T, et al. A new therapeutic strategy for recurrent ovarian cancer – bevacizumab beyond progressive disease. Healthcare. 2019;7:3. doi:10.3390/healthcare703010930497933
   PubMed Web of Science ®Google Scholar
• Lee EK, Konstantinopoulos PA. Combined PARP and Loibl S, Burchardi N immune checkpoint inhibition in ovarian cancer. Trends Cancer. 2019;5(9):524–528. doi:10.1016/j.trecan.2019.06.00431474356
   PubMed Web of Science ®Google Scholar